News | August 14, 2024
Marksans Pharma Q1 FY25 revenue up 18%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
This project is supported by the Irish Government through IDA Ireland
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Revolutionary technology will further boost OneSource’s scientific services offerings
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
These gummies are specially formulated for both kids and adults to nourish the eyes and promote optimal vision development
Subscribe To Our Newsletter & Stay Updated
